Clinical Research Directory

Inclusion Criteria: 1. Age 6-18 years, male or female; 2. Histologically confirmed classic Hodgkin lymphoma; 3. Newly diagnosed, previously untreated patients; 4. Subjects must have at least one measurable lesion, defined as: a lymph node lesion with the longest diameter \>1.5 cm on CT cross-sectional imaging; or an extranodal lesion with the longest diameter \>1.0 cm; 5. ECOG performance status (PS) 0-2; 6. Life expectancy ≥3 months; 7. All screening laboratory tests must be performed as required by the protocol and within 7 days prior to enrollment. The laboratory values obtained at screening must meet the following criteria: 8. Hematology (without blood transfusion, G-CSF, or medication to correct abnormalities within 14 days prior to screening): * Hemoglobin (Hb) ≥70 g/L; * Absolute neutrophil count (ANC) ≥0.5×10⁹/L; * Platelet count (PLT) ≥30×10⁹/L; 9. Biochemistry: * Direct bilirubin (DBIL) \<2 × upper limit of normal (ULN); * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN; * Serum creatinine clearance ≥40 mL/min; 10. The patient or his/her legal guardian has signed the informed consent form (ICF) and voluntarily agrees to participate in this study. Exclusion Criteria: 1. Histopathologically confirmed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL); 2. Prior anti-tumor therapy for classic Hodgkin lymphoma (cHL); 3. Patients with central nervous system (CNS) involvement by lymphoma; 4. Inability to swallow oral medication, or any other factor affecting oral drug administration and absorption; 5. Presence of any active, known, or suspected autoimmune disease (subjects who are in a stable condition and do not require systemic immunosuppressive therapy are permitted to enroll); 6. Use of immunosuppressive agents, including systemic corticosteroids, within 14 days prior to study drug administration (use of ≤10 mg/day prednisone or equivalent is permitted); 7. History of other malignancies within the past 5 years; 8. Severe cardiac dysfunction with ejection fraction (EF) \<50%, or severe cardiac arrhythmia; 9. Any arterial thromboembolic event within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack; 10. Active hepatitis B or hepatitis C infection; 11. History of stroke or intracranial hemorrhage within the past 6 months; 12. Known history of human immunodeficiency virus (HIV) positivity.